USV Launches Liralin Range for Diverse Group of Type 2 Diabetes Patients
USV Pvt. Ltd, a leading drug manufacturer in the diabetes & cardiology segment, has announced the launch of the Liralin Range for the treatment of type 2 diabetes in Indian patients.
USV's Liralin Range is launched in 3 SKU forms: Liralin, Liralin DP & Liralin M. Liralin M will be introduced soon.
Liralin contains Linagliptin 5 mg, whereas Liralin DP is an FDC of Linagliptin 5 mg & Dapagliflozin 10 mg. Liralin M is an FDC containing Linagliptin 5 mg & Metformin 1000 mg
Liralin DP is available at INR 19.9/- per tablet, while Liralin is priced at INR 11.9/- per tablet.
Linagliptin has multiple clinical and safety advantages, making it potentially an evergreen OAD agent as monotherapy and in combination with other agents.
Disclaimer: This post has been published under MD Brand Connect Initiative and is sponsored by USV Private Limited.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd